0001213900-24-076111.txt : 20240905 0001213900-24-076111.hdr.sgml : 20240905 20240905161559 ACCESSION NUMBER: 0001213900-24-076111 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240905 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CITIUS ONCOLOGY, INC. CENTRAL INDEX KEY: 0001851484 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41534 FILM NUMBER: 241281594 BUSINESS ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: (908) 967-6677 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVE, STREET 2: SUITE 2446 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: TenX Keane Acquisition DATE OF NAME CHANGE: 20210315 8-K 1 ea0213635-8k_citius.htm CURRENT REPORT
false 0001851484 0001851484 2024-09-05 2024-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) September 5, 2024

 

 

 

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41534   99-4362660

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(IRS Employer

Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ   07016
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 967-6677

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock   CTOR   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On September 5, 2024, Citius Oncology, Inc. issued a press release to announce that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

  

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is filed herewith:

 

Exhibit No.   Description

99.1

  

Press Release dated September 5, 2024.

104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CITIUS ONCOLOGY, INC.
       
Date: September 5, 2024 /s/ Leonard Mazur
    Leonard Mazur
    Chairman and Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea021363501ex99-1_citius.htm PRESS RELEASE DATED SEPTEMBER 5, 2024

Exhibit 99.1

 

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

 

CRANFORD, N.J., Sept. 5, 2024 -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR) and Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). LYMPHIR is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with Cutaneous T-cell Lymphoma (CTCL).

 

LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory CTCL after at least one prior systemic therapy, was recently approved by the U.S Food and Drug Administration (FDA). The approval of LYMPHIR is based on results from the Phase 3 Pivotal Study 302 (NCT01871727) of CTCL patients who had previously received at least one systemic treatment. LYMPHIR is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs.

 

“The inclusion of LYMPHIR in the NCCN Guidelines is a testament to the clinical evidence supporting this therapy, and further supports healthcare professionals in considering LYMPHIR as part of the recommended treatment protocols for CTCL. We are grateful to the NCCN board for its recognition of LYMPHIR, paving the way for expanded access to this important treatment option,” stated Leonard Mazur, CEO of Citius Pharma and Citius Oncology.

 

“NCCN guidelines are widely regarded as the gold standard for clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S. We believe that LYMPHIR has the potential to improve CTCL patient outcomes, and expect its addition to the NCCN Guidelines may aid adoption and ease reimbursement, particularly for the anticipated patients that qualify for Center for Medicare and Medicaid (CMS) coverage,” added Mazur.

 

About LYMPHIR™ (denileukin diftitox-cxdl)

 

LYMPHIR is a targeted immune therapy for r/r (R/R) CTCL indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

 

In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia.

 

 

 

 

About Cutaneous T-cell Lymphoma

 

Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and Sézary Syndrome (SS) comprise the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify, there is currently no curative therapy for advanced CTCL.

 

INDICATION

 

LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

 

IMPORTANT SAFETY INFORMATION

 

BOXED WARNING: CAPILLARY LEAK SYNDROME

 

Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.

 

WARNINGS AND PRECAUTIONS

 

Capillary Leak Syndrome

 

LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.

 

As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred.

 

Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.

 

Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL.

 

2

 

 

Visual Impairment

 

LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment.

 

Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.

 

Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity.

 

Infusion-Related Reactions

 

LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4% [see Adverse Reactions (6.1)]. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.

 

Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion [see Dosage and Administration (2.3)]. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.

 

Interrupt or discontinue LYMPHIR based on severity [see Dosage and Administration (2.4)]. Institute appropriate medical management.

 

Hepatotoxicity

 

LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved [see Adverse Reactions (6.1)]. Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.

 

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.

 

Embryo-Fetal Toxicity

 

Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.

 

ADVERSE REACTIONS

 

The most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome

 

3

 

 

USE IN SPECIFIC POPULATIONS

 

Pregnancy

 

Risk Summary

Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.

 

Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus.

 

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

 

Lactation

 

Risk Summary

No data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.

 

Females and Males of Reproductive Potential

 

Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.

 

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR.

 

Contraception

 

Females

Advise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.

 

Infertility

 

Males

Based on findings in rats, male fertility may be compromised by treatment with. The reversibility of the effect on fertility is unknown.

 

Pediatric Use

Safety and effectiveness of LYMPHIR in pediatric patients have not been established.

 

Geriatric Use

Of the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

 

4

 

 

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Pharmaceuticals at 1-844-459-6744.

 

Please read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR™ which will be available in the next few days.

 

About Citius Oncology, Inc.

 

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. Citius Pharmaceuticals owns approximately 90% of Citius Oncology. For more information, please visit www.citiusonc.com.

 

About Citius Pharmaceuticals, Inc.

 

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns approximately 90% of Citius Oncology. For more information, please visit www.citiuspharma.com.

 

Forward-Looking Statements

 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our need for substantial additional funds; Citius Pharma’s ability to meet Nasdaq’s continued listing standards; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings which are available on the SEC’s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023, and updated by our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Investor Relations for Citius Pharmaceuticals:

 

Investor Contact:

 

Ilanit Allen

ir@citiuspharma.com

908-967-6677 x113

 

Media Contact:

 

STiR-communications

Greg Salsburg

Greg@STiR-communications.com

 

5

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 ctor-20240905.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ctor-20240905_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ctor-20240905_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Sep. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 05, 2024
Entity File Number 001-41534
Entity Registrant Name Citius Oncology, Inc.
Entity Central Index Key 0001851484
Entity Tax Identification Number 99-4362660
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11 Commerce Drive
Entity Address, Address Line Two 1st Floor
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code 908
Local Phone Number 967-6677
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CTOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /R!)5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #\@259-:%AC.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VVM8.CFHGA2$%Q0O(5D=C?8_"$9:??M;>MN%]$'\)B97[[Y M!J;34>B0\#F%B(DLYJO1]3X+'3?L0!0%0-8'="J74\)/S5U(3M'T3'N(2G^H M/4+-^0TX)&44*9B!15R)3'9&"YU044@GO-$K/GZF?H$9#=BC0T\9JK(")N>) M\3CV'5P ,XPPN?Q=0+,2E^J?V*4#[)0'MZ?%G6+:S/ MI+S&Z5>V@HX1-^P\^;6YN]\^,%GS^KK@MP5OMS4752O:YGUV_>%W$7;!V)W] MQ\9G0=G!K[N07U!+ P04 " #\@259F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M /R!)5DQ"VUB>P0 +81 8 >&PO=V]R:W-H965T&UL MC9AO;^HV%,;?[U-8F31M4MO$*03H (E"NW7WWI85[JZT:2],8L!J$F>V4^#; M[SA PKIP0E^4_#M/?CD^?GR2_D:J-[WFW)!M$J=ZX*R-R>Y<5X=KGC!](S.> MPIFE5 DSL*M6KLX49U$1E,2N[WF!FS"1.L-^<6RJAGV9FUBD?*J(SI.$J=T] MC^5FX%#G>.!5K-;&'G"'_8RM^(R;K]E4P9Y;JD0BX:D6,B6*+P?.B-[=^X$- M**[X0_"-/MDF]E$64K[9G:=HX'B6B,<\-%:"P<\['_,XMDK \<]!U"GO:0-/ MMX_JC\7#P\,LF.9C&7\3D5D/G*Y#(KYD>6Q>Y>97?GB@MM4+9:R+_V2SO[;M M.23,M9')(1@($I'N?]GVD(B3 -\_$^ ? OR">W^C@G+"#!OVE=P09:\&-;M1 M/&H1#7 BM:,R,PK."H@SP[%\YZKO&I"R!]SP$':_#_//A,UX=D.\]A7Q/;_U MWW 7"$H,O\3P"[U;#(/\-5IHHV"@_JXCVBNTZA5L]=[IC(5\X$!Y:J[>N3/\ MX7L:>#\C?+O?Z$0+1*B!:J,@*"J*!XC-FJ MC@*/7[)8MVC[%N/IE#R=2WA>^4K8TH:D/;.D-E.XSE@8D6OR MDL*$EZO=%7E*PQN$KUOR=2_A&\-P*A:#:L2WY!/?U1'B2AZDK=NFK2Z6MEZ) MU;L$:\ZVY"D"-K$4(2ML_/R@XHJ]WG7K-O"#P$/PJ%?9IG<)((R"5)E4!=L5 MF1F8!D0J,I8Y)!3R*J/:P6Y0GSQ@D"?>3B^!'$41.**^.FZ0SW =E%(]&2Y) MZ7<$_L8R2;@*.9DH6%0QV&H%H*B!X[#SC:R%Q26I-@7M8RREPB"K98#B1OX1 MQX%%^AY70RD6BDH M;O&?90@YF:YEBBU=#2*]H',=!)T.1E2M#12W]&]*&,/38K;GZ<&!=2T5+M34 M>=!J7:"XC<]D+$)8"],5^0+EK02+:WEPE28>OUH'?-RIIXI?A]8,87[M&T3H MT:"5?5DNZ\>O0:^1K#)_'W?J_Y$]:9T#62,@+ML(>-+RX^X\%P::-+DDU/]Q M\1.9\3"'>JOM/!J4;'U":S S,GS#T"J;]W%?GBL6V1*;[9*%K"VP!H'Q_.45 M(ZE,W<<-^)@5\K -URQ=\;/]8X/0\V@V&?V.,55N[E_DY@_0 :QLEGX!!;.V M+I&QM'[\<$&C,S(H7\X4T\)I? M;*XY@\EI+X#S2RG-<<>^ZY>?:H;_ E!+ P04 " #\@259GZ ;\+$" #B M# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[ M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q MQ'DJ?$,78&F? KP(&K X MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#. MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV0 M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_ MAOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#% MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[ MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS M/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " #\ M@259EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0 M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L# M!!0 ( /R!)5FJQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1 M;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IE ML]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1RE MW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B M]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@ M?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " #\ M@259)!Z;HJT #X 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% M @ _($E6660>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9-- M3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/ MGI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3 M>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+ES MT&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JH MO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-( M9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX: M?^:+X3]>?P%02P$"% ,4 " #\@259!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( /R!)5DUH6&, M[@ "L" 1 " :\ !D;V-0&UL4$L! A0#% @ _($E63$+;6)[! MA$ M !@ ("!#0@ 'AL+W=O,1 !X;"]? M7!E&UL4$L% 3!@ ) D /@( !(4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tenxkeane.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ctor-20240905.xsd ctor-20240905_lab.xml ctor-20240905_pre.xml ea0213635-8k_citius.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0213635-8k_citius.htm": { "nsprefix": "CTOR", "nsuri": "http://tenxkeane.com/20240905", "dts": { "schema": { "local": [ "ctor-20240905.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "ctor-20240905_lab.xml" ] }, "presentationLink": { "local": [ "ctor-20240905_pre.xml" ] }, "inline": { "local": [ "ea0213635-8k_citius.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://tenxkeane.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-09-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0213635-8k_citius.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0213635-8k_citius.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://tenxkeane.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-076111-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-076111-xbrl.zip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�L3U^7=M;0 M7[IL1T]3!C$1MNQ@W*/5-Y4&SB2P\'(JN3M"B_ 0A")ZI!
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ea0213635-8k_citius_htm.xml IDEA: XBRL DOCUMENT 0001851484 2024-09-05 2024-09-05 iso4217:USD shares iso4217:USD shares false 0001851484 8-K 2024-09-05 Citius Oncology, Inc. DE 001-41534 99-4362660 11 Commerce Drive 1st Floor Cranford NJ 07016 908 967-6677 false false false false Common Stock CTOR NASDAQ true false